• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胰高血糖素样肽-1（GLP-1）药物不断增加的益处。

The expanding benefits of GLP-1 medicines.

作者信息

Gonzalez-Rellan Maria J, Drucker Daniel J

机构信息

Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON M5G1X5, Canada.

Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON M5G1X5, Canada.

出版信息

Cell Rep Med. 2025 Jul 15;6(7):102214. doi: 10.1016/j.xcrm.2025.102214.

DOI:10.1016/j.xcrm.2025.102214
PMID:40669447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12281309/
Abstract

GLP-1 medicines, initially developed for blood glucose and weight control, improve outcomes in people with cardiovascular, kidney, liver, arthritis, and sleep apnea disorders, actions mediated in part through anti-inflammatory and metabolic pathways, with some benefits partly independent of the degree of weight loss achieved.

摘要

最初为控制血糖和体重而研发的胰高血糖素样肽-1（GLP-1）药物，可改善患有心血管、肾脏、肝脏、关节炎和睡眠呼吸暂停症的患者的病情，其作用部分通过抗炎和代谢途径介导，部分益处与体重减轻程度无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62cc/12281309/f79b3e22162b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62cc/12281309/f79b3e22162b/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62cc/12281309/f79b3e22162b/gr1.jpg

相似文献

1
The expanding benefits of GLP-1 medicines.胰高血糖素样肽-1（GLP-1）药物不断增加的益处。
Cell Rep Med. 2025 Jul 15;6(7):102214. doi: 10.1016/j.xcrm.2025.102214.
2
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.胰高血糖素样肽-1 受体激动剂对体重减轻的影响：随机对照试验的系统评价和荟萃分析。
BMJ. 2012 Jan 10;344:d7771. doi: 10.1136/bmj.d7771.
3
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].[2型糖尿病新型降糖药物：文献综述]
Ned Tijdschr Geneeskd. 2010;154:A886.
4
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
5
Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study.真实世界临床实践中2型糖尿病患者对胰高血糖素样肽-1受体激动剂反应的异质性：来自糖尿病患者虚拟队列研究（DPV注册研究）——一项IMI-SOPHIA研究的见解
Diabetologia. 2025 May 22. doi: 10.1007/s00125-025-06448-w.
6
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.用于治疗糖尿病和慢性肾脏病患者的胰岛素及降糖药物。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2.
7
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.二肽基肽酶（DPP）-4抑制剂和胰高血糖素样肽（GLP）-1类似物用于预防或延缓2型糖尿病高危人群发生2型糖尿病及其相关并发症。
Cochrane Database Syst Rev. 2017 May 10;5(5):CD012204. doi: 10.1002/14651858.CD012204.pub2.
8
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.七种胰高血糖素样肽-1 受体激动剂和多激动剂在肥胖或超重患者中的减肥作用：一项更新的随机对照试验的系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.
9
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.每周一次胰高血糖素样肽-1 受体激动剂治疗的获益与危害：系统评价和网络荟萃分析。
Ann Intern Med. 2016 Jan 19;164(2):102-13. doi: 10.7326/M15-1432. Epub 2015 Dec 8.
10
Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials.胰高血糖素样肽-1类似物对无糖尿病的肥胖/超重成年人的减肥效果：一项随机对照试验的系统评价和荟萃分析
J Diabetes. 2015 May;7(3):329-39. doi: 10.1111/1753-0407.12198. Epub 2014 Sep 10.

本文引用的文献

1
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.司美格鲁肽治疗代谢功能障碍相关脂肪性肝炎的3期试验
N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30.
2
GLP-1-based therapies for diabetes, obesity and beyond.基于胰高血糖素样肽-1（GLP-1）的糖尿病、肥胖症及其他疾病治疗方法。
Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8.
3
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
司美格鲁肽与有症状外周动脉疾病和2型糖尿病患者的步行能力（STRIDE）：一项3b期、双盲、随机、安慰剂对照试验
Lancet. 2025 May 3;405(10489):1580-1593. doi: 10.1016/S0140-6736(25)00509-4. Epub 2025 Mar 29.
4
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.口服司美格鲁肽与高危2型糖尿病患者的心血管结局
N Engl J Med. 2025 May 29;392(20):2001-2012. doi: 10.1056/NEJMoa2501006. Epub 2025 Mar 29.
5
Proteomic changes upon treatment with semaglutide in individuals with obesity.司美格鲁肽治疗肥胖个体后的蛋白质组学变化。
Nat Med. 2025 Jan;31(1):267-277. doi: 10.1038/s41591-024-03355-2. Epub 2025 Jan 3.
6
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.每周一次司美格鲁肽治疗肥胖合并膝关节骨关节炎患者的疗效
N Engl J Med. 2024 Oct 31;391(17):1573-1583. doi: 10.1056/NEJMoa2403664.
7
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.司美格鲁肽对比安慰剂在射血分数轻度降低或保留的心衰患者中的疗效：SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 随机试验的汇总分析。
Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.
8
The benefits of GLP-1 drugs beyond obesity.胰高血糖素样肽-1（GLP-1）药物在治疗肥胖症之外的益处。
Science. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128. Epub 2024 Jul 18.
9
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.替尔泊肽治疗阻塞性睡眠呼吸暂停和肥胖。
N Engl J Med. 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881. Epub 2024 Jun 21.
10
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.替尔泊肽治疗代谢相关脂肪性肝炎伴肝纤维化
N Engl J Med. 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8.